Live Breaking News & Updates on Clinical Trial Identifier

Ocuphire Pharma Initiates LYNX-1 Phase 3 Study Investigating Nyxol in Night Vision Disturbances
January 05, 2021 07:00 ET
| Source:
Ocuphire Pharma
Ocuphire Pharma
Nyxol is in Late Stage Clinical Development for A New Ophthalmic Indication
Top Line Data from LYNX-1 Expected 3Q2021
FARMINGTON HILLS, Mich., Jan. 05, 2021 (GLOBE NEWSWIRE) Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders, announced the initiation of patient recruitment and screening in late December for its LYNX-1 Phase 3 registration study evaluating the safety and efficacy of Nyxol
® in night vision disturbances (NVD) at multiple sites in the US. ....

Marguerite Mcdonald , Corey Davis , Ocuphire Pharma , Jay Pepose , Mina Sooch , Late Stage Clinical Development , Langone Medical Center , Pepose Vision Institute , Pharma Inc , Washington University School Of Medicine , Ocuphire Pharma Inc , New Ophthalmic , Online Data , Clinical Ophthalmology , Washington University School , Chief Executive Officer , Nyxol Phase , New Drug Application , Clinical Trial Identifier , Eye Drops , Private Securities Litigation Reform Act , Nasdaq Ocup , மார்குரைட் மக்டொநல்ட் , கோரி டேவிஸ் , மினா சூச் , தாமதமாக நிலை மருத்துவ வளர்ச்சி ,